Phase 2 Start

UTHR: Phase2_Start: EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)

Name: Phase2_Start: EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)
Start: 2026-11-01
End: 2026-11-01

November 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: November 1, 2026
Company: UNITED THERAPEUTICS Corp (UTHR)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start

Phase2_Start: EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)

November 1, 2026

UTHR overview →

Company: UNITED THERAPEUTICS Corp (UTHR)

Other upcoming events for UTHR

Phase 2 StartPhase2_Start: Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

Nov 1, 2026